Global Oncology Academy - Global Oncology Academy

Global Oncology Academy

Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Popular

Exploring Combination Treatment in ER+/HER2- Breast Cancer
Exploring Combination Treatment in ER+/HER2- Breast Cancer
Project Oncology®
Exploring Combination Treatment in ER+/HER2- Breast Cancer
Charles Turck, PharmD, BCPS, BCCCP; Wassim Mchayleh, MD, MBA, FACP
- Charles Turck, PharmD, BCPS, BCCCP
- Wassim Mchayleh, MD, MBA, FACP
Emerging Endpoints for Evaluating Treatment Benefit in pLGG
Emerging Endpoints for Evaluating Treatment Benefit in pLGG
Project Oncology®
Emerging Endpoints for Evaluating Treatment Benefit in pLGG
Shelina Ramnarine, PhD; Mohamed Abdelbaki, MD
- Shelina Ramnarine, PhD
- Mohamed Abdelbaki, MD
CELMoDs in Multiple Myeloma: Optimizing RRMM Treatment With Potent Immunomodulatory Drugs
CELMoDs in Multiple Myeloma: Optimizing RRMM Treatment With Potent Immunomodulatory Drugs
CME/CE
CELMoDs in Multiple Myeloma: Optimizing RRMM Treatment With Potent Immunomodulatory Drugs
Sagar Lonial, MD, FACP
1.00 credit
- Sagar Lonial, MD, FACP
1.00 credit
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients
MinuteCE®
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients
Saad Z. Usmani, MD, MBA; Natalie S. Callander, MD
0.75 program credits
- Saad Z. Usmani, MD, MBA
- Natalie S. Callander, MD
0.75 program credits
Monitoring Toxicities During Advanced Urothelial Carcinoma Treatment
Monitoring Toxicities During Advanced Urothelial Carcinoma Treatment
Project Oncology®
Monitoring Toxicities During Advanced Urothelial Carcinoma Treatment
Petros Grivas, MD, PhD
- Petros Grivas, MD, PhD
What’s Behind the Toxicity? Key Clues in Urothelial Carcinoma
What’s Behind the Toxicity? Key Clues in Urothelial Carcinoma
Project Oncology®
What’s Behind the Toxicity? Key Clues in Urothelial Carcinoma
Petros Grivas, MD, PhD
- Petros Grivas, MD, PhD
Improving Long-Term Adherence to CRC Screening Recommendations
Improving Long-Term Adherence to CRC Screening Recommendations
Clinician's Roundtable
Improving Long-Term Adherence to CRC Screening Recommendations
Brian P. McDonough, MD, FAAFP; David A. Lieberman, MD
- Brian P. McDonough, MD, FAAFP
- David A. Lieberman, MD
Factors Guiding First-Line Treatment Decisions for Myelofibrosis and Anemia
Factors Guiding First-Line Treatment Decisions for Myelofibrosis and Anemia
Project Oncology®
Factors Guiding First-Line Treatment Decisions for Myelofibrosis and Anemia
Charles Turck, PharmD, BCPS, BCCCP; Douglas A. Tremblay, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Douglas A. Tremblay, MD

Medical News

Medical News
ROI Dilation Disrupts Pediatric Brain Tumor ADC Radiomics
08/24/2026
Read more
Medical News
Mental Health Comorbidity Raises Acute Care Use in Cancer
08/17/2026
Read more
Medical News
BACE Added to Tislelizumab Improved Response in Bulky NSCLC
08/17/2026
Read more
Medical News
CT Body Composition Misses Cancer Nutritional Risk
08/17/2026
Read more

CME/CE

MinuteCE®
The Frontline Imperative: Integrating Anti-CD38–Based Regimens Into Multiple Myeloma Care in Community Practice
Saad Z. Usmani, MD, MBA; Natalie S. Callander, MD
0.75 credits 4 episodes
- Saad Z. Usmani, MD, MBA
- Natalie S. Callander, MD
0.75 credits 4 episodes
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients
MinuteCE®
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients
Saad Z. Usmani, MD, MBA; Natalie S. Callander, MD
0.75 program credits
- Saad Z. Usmani, MD, MBA
- Natalie S. Callander, MD
0.75 program credits
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma
MinuteCE®
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma
Saad Z. Usmani, MD, MBA
0.75 program credits
- Saad Z. Usmani, MD, MBA
0.75 program credits
CME/CE Virtual Event
Targeting TROP2 in EGFR-Mutated Advanced NSCLC: Navigating the ADC Revolution After TKI Failure
Multiple dates available
0.50 credits

Clinical Practice

3-Year FIREFLY-1 Findings in pLGG: A Look at Long-Term Outcomes
3-Year FIREFLY-1 Findings in pLGG: A Look at Long-Term Outcomes
Project Oncology®
3-Year FIREFLY-1 Findings in pLGG: A Look at Long-Term Outcomes
Alexandria May, PharmD, BCPS; Daniel Landi, MD
- Alexandria May, PharmD, BCPS
- Daniel Landi, MD
Supporting Patients Throughout Urothelial Carcinoma Treatment
Supporting Patients Throughout Urothelial Carcinoma Treatment
Project Oncology®
Supporting Patients Throughout Urothelial Carcinoma Treatment
Petros Grivas, MD, PhD
- Petros Grivas, MD, PhD
Evidence-Based Care for PD-L1-Negative Non-Small Cell Lung Cancer
Evidence-Based Care for PD-L1-Negative Non-Small Cell Lung Cancer
Project Oncology®
Evidence-Based Care for PD-L1-Negative Non-Small Cell Lung Cancer
Steve Jackson, PharmD; Apar Kishor Ganti, MD
- Steve Jackson, PharmD
- Apar Kishor Ganti, MD
- Thomas Marron, MD, PhD
Case Consult: Personalizing First-Line Maintenance Therapy in Advanced Ovarian Cancer
Case Consult: Personalizing First-Line Maintenance Therapy in Advanced Ovarian Cancer
MinuteCE®
Case Consult: Personalizing First-Line Maintenance Therapy in Advanced Ovarian Cancer
Kathleen N. Moore, MD; Ritu Salani, MD
1.00 program credit
- Kathleen N. Moore, MD
- Ritu Salani, MD
1.00 program credit

Programs

Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
MinuteCE®
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
Natalie S. Callander, MD
0.75 program credits
- Natalie S. Callander, MD
0.75 program credits
Counseling Patients on Myelofibrosis Treatment Goals and Expectations
Counseling Patients on Myelofibrosis Treatment Goals and Expectations
Project Oncology®
Counseling Patients on Myelofibrosis Treatment Goals and Expectations
Shelina Ramnarine, PhD; John Mascarenhas, MD
- Shelina Ramnarine, PhD
- John Mascarenhas, MD
- Marina Kremyanskaya, MD
MinuteCE®
Treatment Decisions That Matter: A Case-Based Discussion in Advanced Ovarian Cancer
Kathleen N. Moore, MD; Ritu Salani, MD
1.00 credit 5 episodes
- Kathleen N. Moore, MD
- Ritu Salani, MD
1.00 credit 5 episodes
Case Consult: Treatment Strategies for HER2-Positive Platinum-Resistant Ovarian Cancer
Case Consult: Treatment Strategies for HER2-Positive Platinum-Resistant Ovarian Cancer
MinuteCE®
Case Consult: Treatment Strategies for HER2-Positive Platinum-Resistant Ovarian Cancer
Kathleen N. Moore, MD; Ritu Salani, MD
1.00 program credit
- Kathleen N. Moore, MD
- Ritu Salani, MD
1.00 program credit